Elisabeth Thomassen-Wolf

Elisabeth Thomassen-Wolf has held several positions throughout their career. Elisabeth started as a Postdoctoral Researcher at Immunex Corp from August 1996 to June 1998, focusing on research projects related to the discovery and characterization of IL-1 and IL-1 Receptor family molecules. During their time at MorphoSys, where they worked from July 1998 to January 2008, they held the role of Senior Scientist and Team Leader, overseeing the generation of therapeutic antibodies in collaboration projects and initiating proprietary programs for the company's development. From November 2004 to January 2008, they also served as the Associate Director of Alliance Management, responsible for managing collaborations and alliances related to antibody discovery and generations.

At MorphoSys AG, Elisabeth Thomassen-Wolf started as an Associate Director in Discovery and Antibody Technology, focusing on target scouting and validation. This position lasted from December 2008 to June 2011, during which they led a team responsible for target scouting and the evaluation and selection of targets. Subsequently, they became an Associate Director of Program Scouting and Evaluation, Project & Portfolio Management, from June 2011 to June 2014. In this role, their responsibilities included leading the search and evaluation project team for in-licensing early clinical programs in the field of oncology and autoimmune diseases. Elisabeth designed search criteria, established a search engine, presented selected programs to key opinion leaders and scientific advisory, and managed due diligence processes.

Most recently, Elisabeth Thomassen-Wolf has been working at MorphoSys AG as the Scientific Director, Business Development & Portfolio Management. Elisabeth started this role in January 2020 and continues to hold it. Their responsibilities include scouting and evaluating in-licensing opportunities, managing due diligence activities, and analyzing the competitive landscape in NHL for building into the tafasitamab development and directing commercialization strategies. Elisabeth also plays a key role in out-licensing and partnering efforts, being responsible for generating and presenting information around the tafasitamab program to potential partners and representing the early stage before involving internal experts. Notably, in January 2020, the tafasitamab program was successfully partnered with Incyte.

Elisabeth Thomassen-Wolf began their education journey in 1992 at Ludwig-Maximilians-Universität München, where they pursued a PhD in Immunology/Oncology. Elisabeth dedicated three years to this program, successfully completing their degree in 1995. Following their PhD, Elisabeth joined the Max-Planck Institute in 1995, where they worked as a post-doctoral fellow. During their time there, they focused on the field of Protein/Protein Interaction. Their tenure at the Max-Planck Institute lasted for a year, concluding in 1996.